Holly B Krasa
Overview
Explore the profile of Holly B Krasa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
1418
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lioudis M, Zhou X, Davenport E, Nunna S, Krasa H, Oberdhan D, et al.
BMC Nephrol
. 2023 Jun;
24(1):182.
PMID: 37349694
Background: Tolvaptan slows kidney function decline in patients with autosomal dominant polycystic kidney disease (ADPKD) who are at risk of rapid progression. Given that treatment requires commitment to long-term use,...
2.
DiBenedetti D, Menne H, Paulsen R, Krasa H, Vradenburg G, Comer M, et al.
Neurol Ther
. 2023 Feb;
12(2):571-595.
PMID: 36790638
Introduction: Insight into the relationship between concepts that matter to the people affected by Alzheimer's disease (AD) and the clinical outcome assessments (COAs) commonly used in AD clinical studies is...
3.
Hauber B, Paulsen R, Krasa H, Vradenburg G, Comer M, Callahan L, et al.
Neurol Ther
. 2023 Feb;
12(2):505-527.
PMID: 36763306
Introduction: In this phase of the ongoing What Matters Most study series, designed to evaluate concepts that are meaningful to people affected by Alzheimer's disease (AD), we quantified the importance...
4.
Oberdhan D, Cole J, Atkinson M, Krasa H, Davison S, Perrone R
Clin J Am Soc Nephrol
. 2023 Feb;
18(2):213-222.
PMID: 36754008
Background: Pain has been identified as a core outcome for individuals with autosomal dominant polycystic kidney disease (ADPKD), but no disease-specific pain assessment has been developed using current development methodology...
5.
Zhou X, Davenport E, Ouyang J, Hoke M, Garbinsky D, Agarwal I, et al.
Kidney Int Rep
. 2022 May;
7(5):1037-1048.
PMID: 35570988
Introduction: In 1- and 3-year randomized trials, tolvaptan slowed kidney function decline in subjects with autosomal dominant polycystic kidney disease (ADPKD) at risk of rapid progression. The 3-year trial also...
6.
DiBenedetti D, Slota C, Wronski S, Vradenburg G, Comer M, Callahan L, et al.
Alzheimers Res Ther
. 2020 Aug;
12(1):90.
PMID: 32731886
Background: The What Matters Most (WMM) study was initiated to evaluate symptoms, AD-related impacts, treatment-related needs, preferences, and priorities among individuals with or at risk for Alzheimer's disease (AD) and...
7.
Pergola P, Pecoits-Filho R, Winkelmayer W, Spinowitz B, Rochette S, Thompson-Leduc P, et al.
Pharmacoecon Open
. 2019 Apr;
3(4):463-478.
PMID: 30968369
Background: The cost and health-related quality of life (HRQoL) burden associated with treatments for anaemia of chronic kidney disease (CKD) is not well characterized among non-dialysis-dependent (NDD) patients. Objective: Our...
8.
Spinowitz B, Pecoits-Filho R, Winkelmayer W, Pergola P, Rochette S, Thompson-Leduc P, et al.
J Med Econ
. 2019 Mar;
22(6):593-604.
PMID: 30813807
The overall cost and health-related quality of life (HRQoL) associated with current treatments for chronic kidney disease (CKD)-related anemia are not well characterized. A systematic literature review (SLR) was conducted...
9.
Oberdhan D, Cole J, Krasa H, Cheng R, Czerwiec F, Hays R, et al.
Am J Kidney Dis
. 2017 Nov;
71(2):225-235.
PMID: 29150246
Background: The impact of autosomal dominant polycystic kidney disease (ADPKD) on health-related quality of life (HRQoL) is not well understood due to a lack of instruments specific to the condition....
10.
Willey C, Blais J, Hall A, Krasa H, Makin A, Czerwiec F
Nephrol Dial Transplant
. 2016 Jun;
32(8):1356-1363.
PMID: 27325254
Background: Autosomal dominant polycystic kidney disease (ADPKD) is a leading cause of end-stage renal disease, but estimates of its prevalence vary by >10-fold. The objective of this study was to...